Department of Otorhinolaryngology Head and Neck Surgery, Yan'an People's Hospital, Yan'an, 716000, China.
Medical College of Yan'an University, Yan'an, 716000, China.
J Environ Pathol Toxicol Oncol. 2021;40(3):63-73. doi: 10.1615/JEnvironPatholToxicolOncol.2021038489.
Allergic rhinitis (AR) is a common type of inflammatory disease with symptoms including rhinorrhea, fatigue, sneezing, and disturbed sleep. AR affects nearly 40% of peoples worldwide with the increased numbers of new cases. In this work, the study was conducted to disclose the anti-inflammatory and antiallergic properties of cirsilineol against the ovalbumin (OVA)-sensitized AR in mice. AR was provoked in BALB/c mice through the OVA challenge 30 days along with 10 and 20 mg/kg of cirsilineol treatment. The nasal symptoms, i.e., rubbing and sneezing was monitored after the final OVA challenge. The status of OVA-specific IgE, PGD2, and LTC4 was investigated using assay kits. The status of pro-inflammatory markers also examined using assay kits. The levels of oxidative markers, SOD activity, and pro-inflammatory markers in the spleen mononuclear cells (SMEs) were studied by using respective assay kits. The mRNA expression of TXNIP was assessed using RT-PCR study. The 10 and 20 mg/kg of cirsilineol treatment effectively decreased the sneezing and nasal rubbings in OVA-provoked mice. Cirsilineol also decreased the IgE, PGD2, and LTC4 status in the AR animals. The status of pro-inflammatory markers, i.e., IL-4, IL-5, IL-6, IL-33 and TNF-α was found to be decreased in the cirsilineol administered AR mice. Cirsilineol effectively reduced the ROS and MDA and improved SOD in the OVA-challenged SMCs. The mRNA expression of TXNIP was appreciably suppressed by the cirsilineol treatment. Altogether, these findings proved the beneficial actions of cirsilineol against the OVA-triggered AR in mice. The additional studies on the cirsilineol could lead to the development of new drug for AR management.
变应性鼻炎（AR）是一种常见的炎症性疾病，其症状包括流涕、疲劳、打喷嚏和睡眠障碍。AR 影响全球近 40%的人群，且新病例数量不断增加。在这项工作中，研究了环硅宁醇对卵清蛋白（OVA）致敏 AR 小鼠的抗炎和抗过敏特性。通过 OVA 挑战 30 天，在 BALB/c 小鼠中引发 AR，并同时给予 10 和 20mg/kg 的环硅宁醇治疗。在最后一次 OVA 挑战后监测鼻症状，如揉鼻和打喷嚏。使用试剂盒检测 OVA 特异性 IgE、PGD2 和 LTC4 的状态。使用试剂盒检测促炎标志物的状态。使用相应的试剂盒研究脾单核细胞（SMEs）中的氧化标志物、SOD 活性和促炎标志物的水平。使用 RT-PCR 研究评估 TXNIP 的 mRNA 表达。10 和 20mg/kg 的环硅宁醇治疗可有效减少 OVA 诱发的小鼠打喷嚏和鼻揉。环硅宁醇还降低了 AR 动物的 IgE、PGD2 和 LTC4 水平。在给予环硅宁醇的 AR 小鼠中，促炎标志物，即 IL-4、IL-5、IL-6、IL-33 和 TNF-α 的水平降低。环硅宁醇可有效减少 OVA 挑战的 SME 中的 ROS 和 MDA，并改善 SOD。环硅宁醇处理可显著抑制 TXNIP 的 mRNA 表达。总之，这些发现证明了环硅宁醇对 OVA 诱发的 AR 小鼠的有益作用。对环硅宁醇的进一步研究可能会导致开发新的 AR 管理药物。
